Contributing Member of the Healthcare Councils
Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.
GLG News by this Author
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Systemic mRNA therapy for liver cancer cancer is new direction
February 16, 2009
Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer | www.pipelinereview.com
Systemic micro RNA therapy has great future for liver cancer cancer. Small molecule probes as mRNA inhibitors will open new avenue for cancer therapy basically to liver cancer.
-
Erbitux enhances efficacy in MCRC patients
January 8, 2009
Merck Serono: Study Published In JCO Shows Erbitux Enhances Efficacy In MCRC Patients With KRAS Wild-Type Tumors In 1st-Line Setting | www.medicalnewstoday.com
To treat MCRC patients with KRAS wild type tumors is a challening task. To overcome it the combination therapy of Erbitux and standard oxaliplatin-based chemotherapy (FOLFOX-4) is highly positive news for patients and care givers.
-
Real-Time observation of molecular reactions
January 5, 2009
New Technique Allows Real-Time Observation Of Molecules During Chemical Reactions | www.medicalnewstoday.com
To develop techniques to observe molecular reactions ( chemical and biological) is the holy-gale in the real biological world. Chemical bond formation and breaking are the central dogma in the life process, so to observe the reactions in real time will solve many problems.
-
Future of microRNA molecular test
January 2, 2009
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso | phx.corporate-ir.net
The future of microRNA molecule test is promising. It will open new avenue for personal medicine.
-
January 2, 2009
Glenmark Pharmaceutical's Crofelemer enters phase-3 clinical trials | pharmalicensing.com
Use of Crofelemer for HIV associated Diarrhea will add another arm for HIV patients.
-
NNRs are not thr right target for CDS
December 22, 2008
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia | www.astrazeneca.com
Neuronal Nicotinic receptors are not the right choice for Cognitive Dysfunction in Schizophrenia.
-
Higher Chemodrugs should not be strategy for Leukemia patient
December 18, 2008
Higher Chemo Drug Dose Prolongs Lives of Leukemia Patients | www.washingtonpost.com
Higher chemodrug dose is a bad strategy for APL, AML and CML. Initially it may benefit for long run basis it will many side effects and mortality rate will be higher.
-
December 8, 2008
Generic Heart Drugs as Good as Brand-Name Counterparts | www.washingtonpost.com
Generic heart drugs have equal therapeutic index as their brand counterparts
-
Growth hormone therapy for ALS
December 8, 2008
Growth hormone not beneficial for ALS | pharmalive.com
1. Growth hormone therapy may benefit for ALS 2. Small molecule agonist of IGF-1 have great future in ALS
-
Simvastatin sell will remain as such
December 8, 2008
Lipitor and Simvastatin sell will compete each other based on doctor prescription and patient poplulation.
-
September 15, 2008
Velcade (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma | www.therapeuticsdaily.com
It is very good news atht Velcade approved for previously untreated multiple Myeloma. Velcade has multiple efficacy as treatmnet is concerned for other diseases too ( Diabetes-II, Cardiovascular disease) as the mechanism of action is same for those target ( proteasome inhibitors).
-
Onglyza (saxagliptin) has a great scope for Diabetes-II
September 11, 2008
BMS, AstraZeneca present saxagliptin data | www.fiercebiotech.com
Saxagliptin has good positive resluts in Phase-III trial.Still noe there i snor side effect reported. Thsi drug will compete with Januvia ( merck). But Saxagliptin is better situtaion as the mechanism of action is concerned on DPP-4.
-
This is bad news for Cell Genesys but may use for other treatment
August 29, 2008
Cell Genesys Ends Clinical Trials For Prostate Cancer Treatment | online.wsj.com
1. Radioimmunoassay is very hard to proof the basic biology of metastatic patient. 2. GVAX Immunotherapy is basically modify the GM-CSF, so the exact biology of immune system of the patient should be considered in metastatic stage before use. As the tumor is already metastatic, again modifying GM-CSF will produce unwanted side effect.
-
Temozolomide and Thalidomide combination therapy for Malignant Melanoma
August 26, 2008
Temozolomide And Thalidomide Combination Effective Against Malignant Melanoma Spread To CNS And White Blood Cell Count May Be Prognostic | www.medicalnewstoday.com
1. The phase II clinical trial of the combination thherapy of ( temozolomide and Thalidomide for Malignant Melanoma is very encourganing. It may open new avenue to treat malignant melanoma affecting Brain. 2. This article is important for use of combination therapy for other diseases. 3. May be other GBM drugs and Thalidomide could be used for Brain cancer Glioblastoma multiforme
-
The FInal Cervical cancer Vaccine is media hype
August 22, 2008
Drug Makers’ Push Leads to Cancer Vaccines’ Fast Rise | www.nytimes.com
1. Merck and GSK are pushing too much for Cerival cancer vaccine advertisement. 2. Merck ( Gardasil), and GSK( cervarix) are very tiny age applications, but real disease start after 20, so early vaccination is no use, but Pap smear is more helpful 3. So drug marker push to cancer vaccine lead is only media hype.
-
There is a hope for NHL ( Non-Hodgkin's Lymphoma).
August 21, 2008
1. BiovaxID® is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. 2. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells 3. BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma. 4. Phase III trial results are very encouraging.
-
Byetta sale will reduce after FAD alert
August 19, 2008
FDA Alert: Hemorrhagic or Necrotizing Pancreatitis in Patients Taking Byetta | www.fda.gov
1. As Byetta is not monotherapy and the clinical trial results are not clear about the condition od trial patient, so future of Byetta is blink
-
Imaging and therapeutic agents for Brain tumor ( glioblastoma multiforme)
August 14, 2008
Recent Popular New Reports About Senator Ted Kennedy's Brain Tumor | www.cnn.com
1. Public awareness and budget for research for brain will increase. 2. Federal funding should increase for GBM ( Glioblastoma multiforme) 3. More researchers will join in this field
-
First serum ELISA for hepcidin
August 13, 2008
UCLA And Biotech Company Develop First Blood Test To Measure Key Hormone That Regulates Iron | www.medicalnewstoday.com
Hepcidin the principal iron-regulatory hormone that has been very difficult to measure but earlier it was measured indirect way ( basically measure the iron binding protein transferrin and ferritin). To overcome this difficulty UCLA group developed new procedure to measure it by serum ELISA. It has potential market value.
-
Byetta sale will remain assuch or decrease
August 11, 2008
Lilly Diabetes Drug Shows a Life-Extending Promise | www.nytimes.com
1. The efficacy is not not know about life exdending ( may be the results are coming from heakthy person), so it is not clear. 2. Patient taking injection 2 times is not feasible for long run basis. 3. It is not monotherapy.
- Subscribe to Updates
-
This author consults with leading institutions through GLG
Most Popular Healthcare News
-
February 7, 2012
-
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
-
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
-
Medtech M&A activity accelerates in 2011
November 30, 2011
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.